Acute myeloid leukemia (AML) is a heterogeneous disease with multiple different cytogenetic and molecular aberrations contributing to leukemic transformation. We compared gene expression profiles of 4608 genes using cDNA-arrays from 20 AML patients (nine with À7/del7q and 11 with normal karyotype) with 23 CD34 þ preparations from healthy bone marrow donors. SKI, a nuclear oncogene, was highly up regulated. In a second set of 183 AML patients analyzed with real-time PCR, the highest expression level of SKI in AML with À7/del7q could be confirmed. As previously described, Ski associates with the retinoic acid receptor (RAR) complex and can repress transcription. We wanted to investigate the interference of Ski with RARa signaling in AML. Ski was co-immunoprecipitated and colocalized with RARa. We also found that overexpression of wild-type Ski inhibited the prodifferentiating effects of retinoic acid in U937 leukemia cells. Mutant Ski, lacking the N-CoR binding, was no more capable of repressing RARa signaling. The inhibition by wild-type Ski could partially be reverted by the histone deacetylase blocking agent valproic acid. In conclusion, Ski seems to be involved in the blocking of differentiation in AML via inhibition of RARa signaling.
Introduction
Acute myeloid leukemia (AML) is a clonal disease arising from hematopoetic progenitor cells. A key event in the pathogenesis of AML is the disturbance of transcription factors that control the normal hematopoetic differentiation. 1 As an example, in patients with acute promyelocytic leukemia (APL), the function of the retinoic acid receptor alpha (RARa) is inhibited by translocations that replace the amino-terminal transactivation domain with different repressor proteins. 2 The fusion protein PML-RARa interacts with N-CoR and recruits the mSin3-histone deacetylase (HDAC) complex, decreasing histone acetylation and producing repressive chromatin organization and transcriptional repression. Unlike normal stem cells, cells with this kind of chimeric receptor do not differentiate in response to physiological concentrations of retinoic acid. 3 Higher doses of retinoic acid lead to dissociation of the N-CoR-mSin3-HDAC complex and transcriptional activation. 4 This molecular mechanism accounts for the block in differentiation in APL.
The APL is characterized by a very good prognosis. In our study, we were interested in the better molecular understanding of a clinical homogenous subgroup with a poor prognosis (AML with monosomy 7 or deletion 7q (À7/del7q)). [5] [6] [7] [8] We analyzed samples from AML patients with À7/del7q, AML patients with normal karyotype (without FLT3 mutation) and normal bone marrow stem cells of healthy individuals, by gene expression profiling. Comparison of these three groups showed that the expression of SKI, a nuclear co-repressor of the HDAC complex, is highly upregulated in À7/del7q AML. A further analysis of SKI expression in a larger group of AML patients from different cytogenetic subgroups by real-time PCR confirmed a high SKI expression in À7/del7q AML and to a lesser degree in other cytogenetic subgroups.
A functional involvement of Ski in different signaling pathways and its transforming activity in hematopoetic cells has been described. [9] [10] [11] Because Dahl et al. 12 showed that Ski could be involved in the repression of RAR signaling and we found a lower SKI expression in the more differentiated AML subgroups (e.g. t(15;17)), we decided to further investigate Ski and its interference with the RARa signaling pathway in AML.
Patients, materials and methods

Patients
In total, samples from 201 patients (median age: 60 years; range: 15-87 years; male: n ¼ 95; female: n ¼ 106), treated according to the AML-96 multicenter protocol of the German Sü ddeutsche Hämoblastose Group with a blast count Z60%, were selected. 13 Diagnosis was based on standard criteria including clinical, microscopical and FACS analysis as described.
14 Each patient gave written informed consent to participate in the study. The local ethics committee of the Philipps-University Marburg approved this study.
Twenty of the 201 AML samples were selected for microarray studies. The first subgroup consisted of bone marrow samples from nine patients (median age: 62 years; range: 20-74 years) with aberrations of chromosome 7, either monosomy 7 or deletion of the long arm (del7q). The second group (N ¼ 11; 10 with de novo AML; one with RAEB-T; median age: 57 years; range 36-74 years) was of normal karyotype without Flt3 aberrations. Flt3 mutations were assessed as described.
14 For both groups, only AML bone marrow samples with a blast count X60% were analyzed. The blast count was estimated by standard microscopy and FACS analysis in a central laboratory. Patient characteristics are shown in Supplementary Table 1 .
AML samples for real-time PCR
Samples from 183 AML patients out of 201 patients were analyzed by real-time PCR. Samples from eight patients out of 20, which were analyzed with microarray technology, were included in real-time PCR experiments.
Healthy bone marrow specimens
Twenty-three patients (mean age: 63 years; range: 46-82 years) undergoing total hip arthroplasty, due to osteoarthritis or fracture, were included as control group for array analysis. Neither malignant, chronic inflammatory or systemic diseases were present. Spongy bone tissue was carefully cut into small pieces, rinsed with saline and filtered. CD34 þ selection of the bone marrow cell suspension was performed using magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). This procedure was repeated once (mean purity was 76%). Each patient gave written informed consent. The ethics committee of the Philipps-University Marburg had approved the study.
Cell lines
Cell lines HL-60, Kasumi-1 and U937 were purchased from ATCC and incubated (RPMI1640 þ 10% fetal calf serum (FCS) þ penicillin G (100 U/ml), streptomycin (100 mg/ml)). FCS was used without depletion of retinoic acid because changes in cell differentiation were only seen after addition of supra-physiological levels of retinoic acid. U937/pEGFP-C1, U937/c-Ski wt and U937/c-Ski (L110P) cells were generated as previously described.
15 QT6 (transformed quail fibroblasts 16 ), was grown in Iscoves' modified DMEM (8% FCS, 2% chicken serum, penicillin G (100 units/ml), streptomycin (100 mg/ml)).
RNA extraction
All AML samples were obtained at the time of diagnosis. No CD34 þ selection was made. Patient samples or cell culture were isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). DNase digestion of all samples was performed using the RNase free DNase-Kit (Qiagen, Hilden, Germany). CD34 þ selected bone marrow cells were extracted using RNazol (PEQLAB, Erlangen, Germany). Yield of RNA was measured with Ribogreen Fluorometry. 17 Preamplification of RNA samples and microarray experiments (see Supplementary Information) Real-time PCR analysis.
Microarray expression data were validated using real-time PCR analysis. Reverse transcription (RT) of 1 mg total RNA was performed as described previously 18 or the OMNISCRIPT RT-Kit (Qiagen, Hilden, Germany). Triple reactions were carried out by ABI PRISM 7700 (Applied Biosystems, Foster City, USA) using the detection System QuantiTect SYBR Green PCR Kit (Qiagen) as outlined by the supplier. The data of real-time quantitative PCR were evaluated based on the DDC t -method. b-ACTIN (patient samples and cell lines) or PBGD (32D cells) expression was used as internal reference. Primer pairs specific for KRAS, UBE2D3, DCK, CDK5, VCAM, SKI, RPA3, GTF2B, BTEb1, RFP, FLJ21016, SEC61g, KIAA0010, POLRJ2, SMAD4 and YWHAH are available upon request. In every assay, SKI expression of the cell line Kasumi-1 was used as internal standard.
Plasmid constructs
T7-tagged expression vectors for wild-type Ski (wt-cSki) and Ski(L110P) vectors have been described previously. 15 The expression vectors for RARa and RXRa were kindly provided by Dr T Heinzel, Frankfurt, Germany. For expression and detection in COS-1 cells, human RARa (X06614) cDNA fragment was generated by PCR using primers 5 0 -GCGCGGG AATTCGCCAGCAACAGCAGC-3 0 , 5 0 -GCGCGGTCGACTCAC GGGGAGTGGGT-3 0 , digested with EcoRI/SalI, and cloned into EcoRI/SalI sites of pCMV-Tag2B (Stratagene, La Jolla, CA, USA). The luciferase construct p(RARE)3-tk-luc was kindly provided by Dr Cecile Egly, Strassbourg, France. The b-galactosidase vector pCMVb and the expression vector pEGFP-C1 were purchased from Clontech BD Biosciences, Germany.
Transient transfections and reporter gene assays
QT6 cells were transfected with p(RARE)3-tk-luc(1 mg), expression vectors for RARa and RXRa (2 mg), wt-Ski or Ski(L110P) (2 mg) and pCMVb(1 mg). 19 The total amount of DNA was adjusted with empty vector (pEGFP-C1). For ligand stimulation, cells were treated with 1 mM ATRA and/or 1 mM valproic acid (VPA) for 16 h. Data were plotted relative to b-galactosidase activity. Results were expressed as means7s.d. from three independent experiments.
Expression plasmids were introduced into COS-1 cells using FuGENE 6 (Roche Applied Science). 15 Cells were transfected with FLAG-tagged-RARa plus T7-tagged wt-c-Ski. T7-tagged wt-c-Ski was co-immunoprecipitated with FLAG-tagged-RARa using anti-FLAG antibody or normal IgG.
Immunoprecipitation and Western blot
Transiently transfected COS-1 cells were lysed in Nonidet P-40 buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, and 10% glycerol) containing phosphatase and protease inhibitors. Precleared extracts were incubated with mouse anti-FLAG (M2, Sigma) monoclonal antibody or mouse normal IgG (Santa Cruz Biotechnology). Immunocomplexes were recovered using protein G-Sepharose (Amersham Biosciences), separated on SDS-polyacrylamide gels, and transferred to nitrocellulose membranes (Protran, Schleicher & Schü ll). The primary antibodies used for Western blot were anti-T7 and rabbit anti-FLAG polyclonal antibody (Sigma). Proteins of interest were detected using chemiluminescence (ECL, Amersham Biosciences).
Immunofluorescence
Cultured cells and patient samples were spun down on coverslips by cytospin centrifugation, air-dried and fixed with methanol (5 0 at room temperature), and permeabilized with acetone (2 0 at 201C). 20 Cells were processed as described. 21 Primary antibodies (mouse monoclonal anti-Ski (G8, Kamiya Biomedical Company, Seattle, WA, USA) and rabbit polyconal anti-RARa (C-20): sc551 (Santa Cruz, Heidelberg, Germany)), secondary antibodies (donkey-anti-rabbit Alexa 488 (Invitrogen, Karlsruhe, Germany, 1:500) and donkey anti-mouse tetramethylrhodamine-isothiocyanate (TRITC) (Dianova, Hamburg, Germany, 1:100)) were used. For details see Supplementary Information.
Flow cytometry
Cell lines were harvested and washed twice with FACS buffer (PBS þ 5 mg/ml BSA). Cells (5 Â 10 5 ) were incubated with 10 ml PE-conjugated anti-human CD11b, CD11c or CD34 antibody (Becton Dickinson, Heidelberg, Germany) and analyzed on a FACS-Scan s . PE histograms were obtained by analyzing 15 000-20 000 cells, gated by scatter characteristics. The viability was assessed by propidium iodide staining (1 mg/ml) and cell quest software (version 6.3.1; Becton Dickinson).
Nitro blue tetrazolium reduction assay
The nitro blue tetrazolium (NBT) reduction assay was carried out as described.
15 U937 cells were treated with solvent (ethanol) or ATRA (1 mM). Cell viability was 490% (trypan blue exclusion).
Statistical analysis
Two-sample t-statistics and adjusted P-values were used to identify differentially expressed genes. 22 The adjusted P-values correct for testing 4608 genes at the same time and estimate the overall probability of detecting one false gene. Differences in quantifiable SKI gene expression or other quantifiable parameters between the analyzed subgroups were evaluated by twotailed Mann-Whitney U-test or t-test. Differences in binary parameters were evaluated by two-tailed Fisher's exact test.
Multivariate analyses of the influence of age, cytogenetics (good/standard/poor) and Ski expression (low/high) on the probability of relapse or survival were carried out by Cox regression using the SPSS 11.0 software package (SPSS, Chicago, IL, USA). Po0.05 was considered significant.
Box and whisker plots were used to graphically display the differences in the expression level of SKI (Figure 1a ). 23 
Results
Gene expression analysis shows SKI as upregulated in À7/del7q AML A cDNA chip consisting of 4.608 genes was used to analyze expression profiles in 20 AML patients (nine with À7/del7q and 11 with normal karyotype (FLT3-negative)) and compared them with CD34 þ progenitor cells isolated from healthy human bone marrow (n ¼ 23). In the statistical analysis of gene expression profiles, we found the oncogenes SKI and K-RAS2 among other highly differentially regulated genes (Supplementary Figure 1 and Supplementary Table 2a-c). We further analyzed SKI, because elevated expression of Ski is sufficient to transform embryonic and hematopoetic cells. 10, 11 To validate the cDNA-microarray analysis, relative gene expression levels were measured by real-time PCR in a set of 14 genes that were differentially regulated in AML samples. Twelve out of 14 genes, analyzed by RT-PCR, could be confirmed (Supplementary Table 3 ).
SKI is upregulated in most cytogenetic subgroups
We determined expression levels of SKI in different cytogenetic subgroups of AML. Cytogenetic data were available in 183 out of 189 cases analyzed by real-time PCR. Correlation of SKI expression with the cytogenetic data revealed that SKI expression was very high in blasts from À7/del7q AML patients. SKI was also overexpressed in most subgroups of AML compared with normal CD34 þ stem cells (Figure 1a) , consistent with the array data. We observed differences between normal CD34 þ progenitor cells, and AML with normal karyotype (P ¼ 0.007), AML with À7/del7q (P ¼ 0.008) and for the group of complex or other rare karyotypes (P ¼ 0.002) (Figure 1b) . However, in AML M3 with translocation t (15;17) , expression of SKI in comparison with normal CD34 þ cells was not statistically significant. Out of the 13 analyzed AML-M3 t(15;17) samples, 11 revealed a very low expression level comparable to the expression level of CD34 þ healthy bone marrow cells. Also, we did not observe a difference between AML with translocations involving CBF and normal CD34 þ cells (Figure 1b) .
Mutated Ski(L110P) partially reverts the effect of Ski in an NBT assay
To test whether Ski inhibits RARa signaling as previously described by Dahl et al., we used the monoblastic leukemia cell line U937. 12, 24 Because U937 cells express low levels of endogenous Ski, we infected these cells with recombinant retroviruses expressing Ski, as well as with a blasticidin (Figure 2a and b) . Retroviral expression of Ski led to reduced NBT staining in response to ATRA (Figure 2a and b) . Immunophenotypic and morphological differentiation of transfected U937 cells treated with ATRA is shown in Supplementary Figure 2 .
Expression of Ski(L110P) resulted in a number of NBT-positive cells, comparable to control cells after ATRA incubation (Figure  2a and b) . Western blot confirmed equal levels of Ski expression in wild-type and mutant Ski in U937 cells (Figure 2c) .
To test whether repression of RAR function by Ski required binding to N-CoR, we performed transient transfection experiments in fibroblastic QT6 cells using either wild-type Ski or the point mutant which is unable to interact with N-CoR (SkiL110P). 15 In contrast to wild-type Ski, Ski(L110P) revealed only a partial reduction of the ATRA-induced luciferase activity (Figure 2d ).
Ski binds to RARa and colocalizes in primary AML cells
To investigate a potential interaction of Ski and RARa in vivo, we performed a co-immunoprecipitation (co-IP) analysis. COS-1 cells were co-transfected with constructs encoding FLAGtagged-RARa and T7-tagged wt-cSki. FLAG-tagged-RARa coprecipitates with T7-tagged wt-cSki as shown in Figure 3A , lanes 3 þ 6. Treatment of COS-1 cells with the ligand retinoic acid does not influence the binding of FLAG-tagged-RARa and T7-tagged wt-cSki ( Figure 3A, lanes 1-3 vs lanes 4-6) .
Colocalization of Ski and RARa could be detected using immunofluorescence in myeloblastic cell line U937 and in AML samples, but not in the promyelocytic cell line NB4. As can be seen in Figure 3B , in U937 leukemia cells (e-h), both proteins were partially colocalizing, which can be seen by yellow colorization in the nucleus (h). In contrast, in NB4 cells (i-l), which harbour a t(15;17), Ski could not be detected (j). In panel l (merge) no yellow colorization is present. Panels a-d of Figure 3B show the immunofluorescence of a first diagnosis sample of an AML patient with normal karyotype. Colocalization of Ski and RARa (small speckles) in the nucleus can be seen. Two further patients showed similar results.
The HDAC inhibitor, VPA, partially reverts the repressive effects of Ski N-CoR is associated with HDAC activity and repression of transcription in a HDAC-dependent manner. 25 We used QT6 cells transiently transfected with the reporter gene pRARE-tkluciferase (under the control of retinoic acid response elements) and vectors encoding for RARa and Ski and incubated these cells with either ATRA and/or VPA as indicated (Figure 4a ). Skimediated repression of ATRA-induced luciferase activity was partially antagonized by VPA (Figure 4a) . In U937 cells transfected with wt-c-Ski or vector, the addition of VPA alone Expression of endogenous SKI is higher in a more immature phenotype HL60 cells differentiated by VPA and ATRA expressed lower levels of SKI compared with untreated cells (Figure 4b and c) . In healthy G-CSF mobilized CD34 þ peripheral blood stem cells, we found a higher expression of endogenous SKI in the more immature CD34 þ /CD38À cell fraction compared with the more mature CD34 þ /CD38 þ compartment (Supplementary Figure 2c) .
Discussion
Ski has transforming activity in chicken hematopoietic cells and has been implicated in the regulation of different signaling pathways that control the proliferation and differentiation. 10 First, Ski is a negative regulator of signal transduction through TGF-b in vivo. 26 Second, Ski is a cofactor for repression of the Mad family of transcriptional repressors. 27 Third, Ski represses transcriptional activation by nuclear receptors, for example, RARa. 12 The divergent functions of Ski may be explained by its ability to bind multiple partners.
We analyzed AML with À7/del7q, using gene expression profiling, and found an overexpression of SKI. The analysis of a larger group of AML patients by real-time PCR also showed elevated SKI expression levels in other cytogenetic subgroups. According to the involvement of Ski in the RARa signaling pathway, as described by Dahl et al., 12 we were interested to find out whether the overexpression of SKI might play a role in AML. In line with the data of Dahl et al., 12 who found a binding of Ski to RARa in vitro, we showed the physical interaction of Ski and RARa in vivo in COS-1 cells. Additionally, we could show in vitro that the overexpression of Ski inhibits transactivation of RARa in the presence of ligand, and that Ski and RARa are colocalized in the nucleus of the hematopoetic cell line U937, as well as in primary AML cells. These data showed that Ski indeed binds to RARa and functionally interacts in the nucleus of hematopoetic and leukemic cells.
In APL, the PML-RARa fusion protein causes a strong dominant-negative effect, resulting in a blockade of RARainduced differentiation. 2 The RARa signaling pathway, which is important in myeloid differentiation, might also be partially inhibited by other binding partners in non-APL AMLs. Our hypothesis was that Ski overexpression interferes with RARa signaling, causing a partial inhibition of differentiation and thus contributing to the leukemic phenotype. In tumor cells, it is known that genetic aberrations frequently target alternative proteins involved in the same critical signaling pathway. For instance, Palmero and Peters 28 described a comparable 27 could show that Ski is a component of the HDAC complex and is involved in the transcriptional repression by nuclear hormone receptors. The multiple repression domains of Ski interact with different partners of the HDAC multiple protein complex. Ski binds to N-CoR/SMRT and mSin3A through different repression domains, but seems to mediate transcriptional repression with additional factors. 27 Previously, we could show that the function and interaction of Ski with N-CoR is signal dependent. 15 In contrast to the Ski-mediated repression of the nuclear receptor signaling, repression of TGF-b signaling was N-CoR independent. As demonstrated in Figure 2 , our results of co-IP showed a direct interaction of Ski and RARa, suggesting that Ski exerts its repressive function via the nuclear receptor pathway. Moreover, this repression is N-CoR dependent as shown by the reporter gene assay, using the mutant Ski(L110P), lacking the N-CoR binding (Figure 3 ). Our data suggest that Ski inhibits RARa signaling N-CoR dependent, as one partner of the multiprotein complex of HDACs.
N-CoR, a binding partner of Ski, and SMRT have been implicated in repression of differentiation in acute leukemias. (i) In APL, the interaction of PML-RARa fusion protein with the corepressors was shown to be less sensitive to retinoic acid than interaction with wild-type RARa. 29 (ii) In AML with t(8;21), AML-ETO interacts with N-CoR and represses transcription, causing an inhibition of differentiation. 30, 31 (iii) Acute leukemias with translocations involving TEL also showed an interference with the co-repressor N-CoR. 32 We found that overexpressed SKI inhibits RARa signaling in different cytogenetic subgroups of AML. As described for leukemias (i-iii), where HDAC inhibitors impaired the repression of differentiation, we could show that the HDAC inhibitor VPA partially reverted the effect of overexpressed Ski. Thus, the repression of HDAC-associated differentiation seems to be a more common event in acute leukemias.
To study the clincal relevance of HDAC inhibitors, Kuendgen et al. 33 and our study group 34 investigated the therapy with VPA and VPA/ATRA in patients with myeloid diseases. Kuendgen et al. 33 reported a response rate of 44% in 18 patients with low/ intermediate MDS or secondary AML. Bug et al. 34 investigated the combined therapy with VPA and ATRA. Out of 26 patients with overt AML, only two (8%) achieved an objective response. These data show that VPA/ATRA treatment has an in vivo effect in some patients with myeloid diseases. The involvement of Ski in AML patients treated with VPA/ATRA has to be analyzed in additional trials.
In conclusion, Ski is involved in RARa signaling pathway, and the repressive function can be antagonized by the HDACinhibitor VPA in cell culture experiments. The overexpression of SKI in certain AML patients might be one step of the multistep process of leukemogenesis. 
